Related Experiment Video
Updated: Apr 13, 2026

Measuring the Motor Aspect of Cancer-Related Fatigue using a Handheld Dynamometer
Published on: February 20, 2020
Validation of the PROMIS physical function measures in a diverse US population-based cohort of cancer patients
Roxanne E Jensen1, Arnold L Potosky2, Bryce B Reeve3,4
1Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University, 3300 Whitehaven Street NW, Suite 4100, Washington, DC, 20007, USA. rj222@georgetown.edu.
Purpose:
To evaluate the validity of the Patient-Reported Outcomes Measurement Information System (PROMIS) physical function measures in a diverse, population-based cancer sample.
Methods:
Cancer patients 6-13 months post-diagnosis (n = 4840) were recruited for the Measuring Your Health study. Participants were diagnosed between 2010 and 2013 with non-Hodgkin lymphoma or cancers of the colorectum, lung, breast, uterus, cervix, or prostate. Four PROMIS physical function short forms (4a, 6b, 10a, and 16) were evaluated for validity and reliability across age and race-ethnicity groups. Covariates included gender, marital status, education level, cancer site and stage, comorbidities, and functional status.
Results:
PROMIS physical function short forms showed high internal consistency (Cronbach's α = 0.92-0.96), convergent validity (fatigue, pain interference, FACT physical well-being all r ≥ 0.68), and discriminant validity (unrelated domains all r ≤ 0.3) across survey short forms, age, and race-ethnicity. Known-group differences by demographic, clinical, and functional characteristics performed as hypothesized. Ceiling effects for higher-functioning individuals were identified on most forms.
Conclusions:
This study provides strong evidence that PROMIS physical function measures are valid and reliable in multiple race-ethnicity and age groups. Researchers selecting specific PROMIS short forms should consider the degree of functional disability in their patient population to ensure that length and content are tailored to limit response burden.
Related Concept Videos
Cancer Survival Analysis
Cancer Prevention
Some...
Cancer Prevention
Bioavailability Study Design: Healthy Subjects Versus Patients
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies

